Polyoxidonium lyophilisates for solution for u and I-mest.prim 6mg 5 pcs

$29.72

Polyoxidonium lyophilisates for solution for u and I-mest.prim 6mg 5 pcs

Quantity:

SKU: 1970184861 Categories: , , Tags: ,

Description

Composition
Active substance:
Azoximer bromide – 6 mg;
Excipients:
mannitol – 1.8 mg Povidone K 17 – 1.2 mg
Description:
porous mass of white with a yellowish tinge
Product form:
Lyophilizate for preparation of solution for injection and topical application of 6 mg.
5 vials of medication in blisters made of PVC film. According to one contour cellular packaging together with instructions for use placed in a pile of cardboard or 5 vials together with instructions for use placed in a pile of cardboard with an insert made of cardboard.
Contraindications
Individual hypersensitivity
Pregnancy, lactation
Children up to age 6 months
Acute renal failure
Precautions chronic renal failure (apply no more than 2 times per week).
Dosage
6 mg
Indications
It is used in adults and children 6 months of treatment and prevention of infectious and inflammatory diseases (viral, bacterial and fungal etiology), in the stage of exacerbation and remission.
For the treatment of adults (combination therapy):
chronic recurrent infectious and inflammatory diseases of different localization, bacterial, viral and fungal etiology in the acute stage;
acute viral, bacterial infections of upper respiratory tract, upper and lower respiratory tract, gynecological and urological diseases;
acute and chronic allergic diseases (including hay fever, bronchial asthma, atopic dermatitis), complicated by bacterial, viral or fungal infection;
malignancies during and after chemotherapy and radiation therapy to reduce immunosuppressive, nephrotoxicity and hepatotoxicity of drugs;
generalized forms of surgical infections; to activate regenerative processes (fractures, burns, trophic ulcers);
rheumatoid arthritis, complicated by bacterial, viral or fungal infection, against long-term use of immunosuppressants pulmonary tuberculosis
For the treatment of children over 6 months (combination therapy):
and acute exacerbation of chronic inflammatory diseases of any location (including ENT – sinusitis, rhinitis, adenoiditis hypertrophy pharyngeal tonsil, SARS), caused by pathogens of bacterial, viral, fungal infections, acute allergic and toxic and allergic conditions, complications of bacterial, viral or fungal infection of bronchial asthma complicated by chronic infections of the respiratory tract of atopic dermatitis complicated by purulent infection of intestinal dysbiosis (in combination with specific oh therapy
For the prevention (monotherapy) in children older than 6 months and adults:
Influenza and SARS
postoperative infectious complications
Interaction with other drugs
Azoximer bromide does not inhibit isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, cytochrome P-450, and the drug is compatible with many drugs, including antibiotics, antiviral, antifungal and antihistamines, glucocorticosteroids and cytostatics.
Overdose
Cases of overdose are not logged in.
pharmachologic effect
Pharmacological group:
immunomodulatory agent.
Pharmacodynamics:
Azoximer bromide has a complex action: immunomodulatory, detoxicating, antioxidant, anti-inflammatory moderate.
The basis for an immunomodulatory mechanism of action azoximer bromide is a direct effect on the phagocytic cells and natural killer cells, and stimulation of antibody synthesis of interferon-alpha and interferon-gamma.
Detoxification and antioxidant properties azoximer bromide is largely determined by the structure and nature of the high molecular weight of the drug. Azoximer bromide increases resistance of the organism against both local and generalized infections of bacterial, fungal and viral etiology. Restores immunity in secondary immunodeficiency, caused by different infection, trauma, complications after surgical operations, burns, autoimmune diseases, malignancies, use of chemotherapeutic agents, cytostatic drugs, steroid hormones.
A characteristic feature azoximer bromide topically (intranasal, sublingual) use is the ability to activate the early defense against infection factors: drug stimulates bactericidal properties neutrophils, macrophages, enhances their ability to absorb bacteria improves the bactericidal properties of saliva and mucous secretions of the upper respiratory tract.
Azoximer bromide blocked soluble toxic substances and microparticles has the ability to excrete toxins, heavy metal salts, inhibits lipid peroxidation, both due to the interception of free radicals and by elimination of catalytic ions Fe2 +. Azoximer bromide reduces the inflammatory response by normalizing the synthesis of pro- and anti-inflammatory cytokines.
Azoximer bromide well tolerated, has no mitogenic, polyclonal activity, antigenic properties, has no allergenic, mutagenic, embryotoxic, teratogenic and carcinogenic effects.
Azoximer bromide has no smell and taste, does not have a local irritating effect when applied to the mucous membranes of the nose and oropharynx.
Pharmacokinetics:
Azoximer bromide characterized by a rapid absorption and high velocity distribution in the body. The maximum concentration of drug in the blood after intramuscular administration is achieved after 40 minutes. The half-life for all ages from 36 to 65 hours. High bioavailability more than 90% when administered parenterally.
Azoximer bromide is rapidly distributed to all organs and tissues of the body, it penetrates the blood-brain and blood-barrier. The cumulative effect is not. In the body azoximer bromide undergoes biodegradation to low molecular weight oligomers derived primarily by the kidneys, with faeces – less than 3%.
Pregnancy and breast-feeding
Polioksidoniy® not use this drug to pregnant women and during breast feeding (clinical experience with offline).
In the experimental study drug Polioksidoniy® animals revealed no effect on generative function (fertility) in males and females, embryotoxic and teratogenic effects, influence on fetal growth, when administered as a drug during the pregnancy and lactation.
Conditions of supply of pharmacies
On prescription.
side effects
In applying the drug Polioksidoniy® meet the following general and local reactions:
Not often (> 1/1 000
Very rare (> 1/10 000): increase in body temperature up to 37,3 ° C, mild anxiety, vomiting during the first hour after injection, and allergic reactions.
special instructions
With the development of allergic reactions should stop using Poliokidoniy® drug and consult a doctor.
If necessary Poliokidoniy® discontinuation cancellation can be carried out directly, without the gradual decrease in the dose.
In the case of missing the next dose administration subsequent its application should be performed in the normal mode, as indicated in the instructions or recommended by a doctor. The patient should not double the dose administered to compensate for missed doses.
Do not use the drug if there is visual evidence of his unfitness (stacking fault, change the color of the powder).
When the pain in the injection site of the drug is dissolved in 1 ml of 0.5% solution of procaine (novocaine) in the absence of a patient of individual hypersensitivity to procaine (novocaine). When intravenously (drip) administration should not be dissolved in the protein-containing infusion solutions.
Effect on the ability to drive mechanisms and
Use of the drug Polioksidoniy® does not affect the ability to perform potentially hazardous activities that require high concentration and speed of psychomotor reactions (including the management of vehicles, work with moving machinery).
Storage conditions
In a dry place at a temperature of from 2 to 8 ° C. Keep out of the reach of children
Dosing and Administration
Methods of Use Polioksidoniy® preparation: parenteral, intranasal, sublingual.
Methods of application, dosing regimen, and the need for the multiplicity of subsequent courses of therapy physician selected depending on the disease severity and the age of the patient.
Preparation of solutions for parenteral administration (intramuscular and intravenous) administration For intramuscular formulation Polioksidoniy® 3 mg dissolved in 1 ml (dose of 6 mg in 2 mL) of water for injection or 0.9% sodium chloride solution. After making preparation of the solvent left for 2-3 minutes to swell, then stirred rotational movements without shaking.
For intravenous drip preparation Polioksidoniy® dissolved in 2 ml of sterile 0.9% sodium chloride solution. After making preparation of the solvent left for 2-3 minutes to swell, and then stirred for rotational movements. The calculated dose to the patient is transferred to a sterile bottle / bag with 0.9% sodium chloride solution.
The prepared solution for parenteral administration must not be stored.
The preparation for intranasal and sublingual solution: For children the dose of 3 mg dissolved in 1.0 ml (20 drops).
Dosing and dose in adults
Parenterally (intramuscularly or intravenously) the drug is prescribed for adults in doses of 6-12 mg 1 time per day every day, every other day or 1-2 times a week, depending on the diagnosis and the severity of the disease.
In acute viral and bacterial infections of upper respiratory tract, upper and lower respiratory tract, gynecological and urological diseases: 6 mg daily for 3 days, then every other day course of 10 injections.
In chronic recurrent infectious and inflammatory diseases of different localization, bacterial, viral and fungal etiology, acute stage: 6 mg 5 injections every other day, then two times a week course of 10 injections.
In acute and chronic allergic diseases (including hay fever, bronchial asthma, atopic dermatitis), complications of bacterial, viral and fungal infection: 6-12 mg, rate of 5 injections.
In rheumatoid arthritis, complicated by bacterial, viral or fungal infection, against long-term use of immunosuppressants: 6 mg 5 injections every other day, then two times a week course of 10 injections.
In generalized forms of surgical infections: 6 mg daily for 3 days, then every other day course of 10 injections.
For the activation of regenerative processes (fractures, burns, trophic ulcers): 6 mg for 3 days, then every other day course of 10 injections.
For prevention of postoperative infectious complications: 6 mg 5 injections every other day.
Pulmonary tuberculosis: 6 mg 2 times a week course of 20 injections.
In cancer patients:
before and during chemotherapy to reduce immunosuppressive, hepato- and nephrotoxic action of chemotherapeutic agents of 6 mg after 10 day course of injections; further administration frequency is determined by the doctor depending on tolerability and duration of chemo- and radiotherapy;
immunosuppressive effect for preventing tumors, for the correction of immunodeficiency after chemo- and radiotherapy after surgical removal of the tumor demonstrated prolonged use Polioksidoniy® preparation (from 2-3 months to 1 year) at 6 mg 1-2 times a week. When assigning long course is not marked effect of accumulation, toxicity and addiction.
Intranasally administered at 6 mg per day (3 drops in each nostril 3 times daily – for 10 days):
for the treatment of acute exacerbations of chronic infections and upper respiratory tract;
to enhance mucosal regenerative processes;
for the prevention of complications and relapse of chronic diseases;
for the prevention of influenza and acute respiratory viral infections.
Dosing and Administration in children
Methods of Use Polioksidoniy® preparation: parenteral, intranasal and sublingual. Methods of application are chosen doctor depending on the patient’s age and disease severity.
Parenterally (intramuscularly or intravenously) administered to children 6 months at a dose of 0.1 to 0.15 mg / kg daily, every other day or 2 times a week course of 5-10 injections.
Intranasally and sublingually daily at a daily dose of 0.15 mg / kg to 10 days a course.
The drug is administered by 1-3 drops into one nostril or sublingually at intervals of not less than 1-2 hours, 2-3 hours per day.
One drop (0.05 ml) of the prepared solution contained 0.15 mg of drug.
Calculation of a daily dose for intranasal and sublingual administration are presented below:
5 kg – 5 drops
10 kg – 10 drops
15 kg – 15 drops
20 kg – 20 drops
When the child body weight over 20 kg the daily dose calculation is made of the rate of 1 drop per 1 kg of body weight, but no more than 40 drops (6 mg of active substance).
The prepared solution for intranasal and sublingual administration may be stored at room temperature in a packaging manufacturer to 48 hours.
Recommended treatment regimens in children
parenteral:
In acute and acute exacerbations of chronic inflammatory diseases of any location (including ENT – sinusitis, rhinitis, adenoiditis hypertrophy pharyngeal tonsil, SARS), caused by pathogens of bacterial, viral, fungal infections: 0.1 mg / kg 3 days row, then every other day course of 10 injections.
In acute allergic and toxic and allergic conditions (including bronchial asthma, atopic dermatitis), complications of bacterial, viral and fungal infection: intravenously at a dose of 0.1 mg / kg, daily 3 days, then every other day, in the course of 10 injections combined with basic therapy.
Intranasal daily 1-2 drops in each nostril, 3 times a day rate of up to 10 days
In acute and chronic rhinitis, rhinosinusitis, adenoids (treatment and prevention of exacerbation);
For preoperative preparation of patients for surgical interventions with ENT pathology and postoperatively to prevent infectious complications or recurrent disease;
Treatment and prevention of influenza and SARS other (within one month before the expected epidemic) at any time after initiation of the disease and during convalescence);
Sublingually child early, pre-school age and younger daily at a daily dose of 0.15 mg / kg in two divided doses for 10 days:
When adenoiditis tonsillar hypertrophy (both conservative treatment component);
For preoperative and postoperative rehabilitation;
For the prevention of seasonal exacerbations of chronic lesions oropharyngeal infections, upper respiratory tract, the inner and middle ear;
For the treatment of intestinal dysbiosis (in combination with basic therapy) within 10 days.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Petrovax

There are no reviews yet.

Add your review